A cartilage building block taken mainly for joint comfort. Evidence for easing wear-and-tear joint pain is genuinely split between modest benefit and none, hinging largely on product quality. It may slightly slow cartilage loss, and regular users show lower death and cancer rates, though only as associations. Very safe; the longevity promise is unproven but worth watching. (Full Review)
| Marker | Target | Why |
|---|---|---|
| hs-CRP (high-sensitivity C-reactive protein) | < 1.0 mg/L | Tracks systemic inflammation, the proposed longevity mechanism |
| INR (international normalized ratio) | ≈2.0–3.0 on warfarin; ~0.8–1.1 if not | Detects the main safety interaction, increased bleeding effect |
| Fasting glucose / HbA1c | Fasting 70–90 mg/dL; HbA1c < 5.4% | Screens for glucose changes, chiefly a concern of the glucosamine partner |
| Joint imaging (X-ray joint-space width) | Stable joint-space width over time | Objective measure of structural progression in osteoarthritis |
Cadence: Reassess joint benefit at 8–12 weeks and again at 3–6 months; on anticoagulants, check INR at baseline and 2–4 weeks; imaging spaced over 1–2 years.